Atara Biotherapeutics Inc (NASDAQ:ATRA) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,533,903 shares, a growth of 1.6% from the March 15th total of 3,479,413 shares. Based on an average daily volume of 318,209 shares, the days-to-cover ratio is presently 11.1 days.
Atara Biotherapeutics (NASDAQ:ATRA) opened at 15.15 on Friday. The company’s market capitalization is $440.70 million. Atara Biotherapeutics has a 12 month low of $12.45 and a 12 month high of $25.73. The stock’s 50 day moving average is $16.87 and its 200-day moving average is $16.86.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, March 9th. The biotechnology company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.35. On average, analysts expect that Atara Biotherapeutics will post ($3.83) EPS for the current year.
In other Atara Biotherapeutics news, CFO John Mcgrath sold 24,000 shares of the firm’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $20.00, for a total value of $480,000.00. Following the transaction, the chief financial officer now directly owns 126,827 shares of the company’s stock, valued at $2,536,540. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gad Soffer sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $20.00, for a total transaction of $50,000.00. Following the completion of the transaction, the executive vice president now directly owns 266,527 shares in the company, valued at $5,330,540. The disclosure for this sale can be found here. Insiders have sold 142,958 shares of company stock worth $2,630,542 over the last three months. 16.10% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ATRA. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Atara Biotherapeutics during the first quarter worth approximately $132,000. Elkfork Partners LLC purchased a new position in Atara Biotherapeutics during the fourth quarter worth approximately $135,000. DekaBank Deutsche Girozentrale purchased a new position in Atara Biotherapeutics during the first quarter worth approximately $185,000. BlackRock Inc. increased its position in Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the biotechnology company’s stock worth $272,000 after buying an additional 6,597 shares in the last quarter. Finally, American International Group Inc. increased its position in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares in the last quarter. Hedge funds and other institutional investors own 77.48% of the company’s stock.
A number of equities analysts have issued reports on ATRA shares. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Saturday, March 11th. Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Finally, Citigroup Inc set a $10.00 price target on shares of Atara Biotherapeutics and gave the stock a “sell” rating in a research report on Thursday, March 16th. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $24.00.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.